Press Releases

Press Releases

    Date Title View
    11/13/20
    Summary ToggleNew Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration
    PDF Version
    11/13/20
    Summary ToggleHorizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala
    PDF Version
    11/12/20
    Summary ToggleHorizon Therapeutics plc to Participate in Upcoming Investor Conferences
    PDF Version
    11/02/20
    Summary ToggleHigher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
    PDF Version
    11/02/20
    Summary ToggleHorizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance
    11/02/20
    Summary ToggleHorizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
    PDF Version
    10/30/20
    Summary ToggleChicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year
    PDF Version
    10/30/20
    Summary ToggleNew TEPEZZA® (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting
    PDF Version
    10/29/20
    Summary ToggleHorizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout
    PDF Version
    10/26/20
    Summary ToggleHorizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business
    PDF Version
    Displaying 11 - 20 of 551 results